Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
BeiGene
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed locally advanced or metastatic solid tumors with a high prevalence of mucin-1 (MUC1) expression
At least 1 measurable lesion per RECIST v1.1
Stable Eastern Cooperative Oncology Group Performance Status of ≤ 1
Adequate organ function
Willing to use a highly effective method of birth control
You may not be if
History of prior ≥ Grade 3 Cytokine Release Syndrome (CRS)
History of severe Infusion-Related Reactions (IRRs), allergic reactions, or hypersensitivity to any ingredients or components of the study treatments
Infection requiring systemic (oral or intravenous) therapy ≤ 14 days before the first dose of study drug(s), or participants with symptomatic COVID-19 infection
Active leptomeningeal disease or uncontrolled, untreated brain metastasis
Active autoimmune disease or history of autoimmune disease(s) that may relapse
Clareo Health | A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
